We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01577004
Recruitment Status : Completed
First Posted : April 13, 2012
Last Update Posted : April 13, 2012
Information provided by (Responsible Party):
Mélanie Plourde, Universitaire de Sherbrooke

Brief Summary:

BACKGROUND: Compared to the epsilon 2 or epsilon 3 alleles, the epsilon 4 allele of apolipoprotein E (ApoE4) is associated with twice the prevalence of late-onset Alzheimer's disease (AD). Epidemiological studies show that risk of AD varies inversely with consumption of omega-3 fatty acids from fish and seafood. Despite apparently lower fish intake in AD, pooled analysis of the literature shows that plasma and brain docosahexaenoic acid (DHA) is actually the same in AD as in healthy age-matched controls. Fish oil trials in AD are also not convincing. We recently shown that ApoE4 carriers have 41% higher fasting plasma EPA and DHA compared to non-carriers, but the plasma EPA and DHA response to fish oil in ApoE4 carriers was half that seen in non-carriers.

HYPOTHESES: (i) Carriers of ApoE4 have altered metabolism of carbon-13 (13C)-DHA as well as EPA and DHA provided in a dietary supplement. (ii) A dietary supplement of EPA+DHA will improve cognitive performance but only in non-carriers of ApoE4.

OBJECTIVES: In both carriers and non-carriers of ApoE4, to compare whether- i) ApoE4 alters incorporation of 13C-DHA into plasma lipids or its beta-oxidation.

ii) 13C-DHA metabolism changes while on a dietary supplement of EPA+DHA; iii) Better cognitive performance occurs while on EPA+DHA and is linked to raising plasma EPA and/or DHA.

EXPERIMENTAL METHODS: Participants older than 50 y old and not demented were enrolled. DHA metabolism was evaluated using both 13C-DHA and an EPA+DHA supplement (2.4 g/d for 5 mo; n = 20/gp). Before and in the last month of supplementation, plasma uptake and beta-oxidation of 50 mg of 13C-DHA was followed during one month. Blood omega-3 fatty acids was evaluated monthly during the supplementation period. Cognitive testing was performed before and 4 months after starting the omega-3 fatty acid supplement.

IMPLICATIONS: This project will help explain the apparent link that is newly emerging between ApoE polymorphisms, altered omega-3 fatty acid metabolism and risk of cognitive decline, and should help in the development of nutraceutical-based clinical trials using fish oil for the elderly.

Condition or disease Intervention/treatment
Healthy Dietary Supplement: omega-3 fatty acid

Detailed Description:
To come

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?
Study Start Date : July 2009
Primary Completion Date : October 2011
Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Omega-3 fatty acid supplement
Data obtained after the intervention was compared to baseline data
Dietary Supplement: omega-3 fatty acid
Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
Other Name: Ocean Nutrition, Dartmouth, NS

Primary Outcome Measures :
  1. 13C-DHA incorporation into plasma lipids or beta-oxidation. [ Time Frame: one month ]
    Before and in the last month of supplementation, plasma incorporation and beta-oxidation of 50 mg of 13C-DHA will be followed during one month. Blood and breath samples will be collected at time 0 h, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, 7 d, 14 d, 21 d, and 28 d.

Secondary Outcome Measures :
  1. Cognitive performance compared to baseline [ Time Frame: 5 month ]
    Cognitive testing was done before and 4 months after starting the omega-3 fatty acid supplement.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • MCI will be defined by Winblad et al. (33), with diagnosis confirmed by a geriatrician through neuropsychological evaluation done within the last 6 months.
  • if diagnosis was done more than 6 months ago, the subject will be re-evaluated before inclusion to confirm MCI rather than conversion to AD.

Exclusion Criteria:

  • tobacco
  • malnutrition (assessed from blood albumin, haemoglobin and lipids)
  • subjects already taking an EPA+DHA supplements
  • swallowing problems, uncontrolled diabetes (raised fasting glucose, haemoglobin A1c)
  • uncontrolled thyroid disease
  • severe renal failure
  • chronic immune condition or inflammation (raised C-reactive protein, white cell count)
  • cancer
  • recent major surgery or cardiac event
  • uncorrected visual or hearing problems
  • dementia
  • ongoing or past severe drug or alcohol abuse
  • psychiatric difficulties or depression as evaluated by the geriatric depression scale test (34)
  • use of psychotropic medications except for short-acting benzodiazepines taken before sleep.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01577004

Canada, Quebec
Melanie Plourde
Sherbrooke, Quebec, Canada, J1H4C4
Sponsors and Collaborators
Université de Sherbrooke
Principal Investigator: Melanie Plourde, Ph.D. Université de Sherbrooke

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Mélanie Plourde, Assistant Professor, Universitaire de Sherbrooke
ClinicalTrials.gov Identifier: NCT01577004     History of Changes
Other Study ID Numbers: AFMNet-1
Discovery grant ( Other Grant/Funding Number: Advanced Foods and Materials Network )
First Posted: April 13, 2012    Key Record Dates
Last Update Posted: April 13, 2012
Last Verified: April 2012

Additional relevant MeSH terms:
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders